Abstract
With eleven therapeutic antibodies approved worldwide and many more in clinical trials, research on antibody engineering has continued to escalate and expand. This review covers recent progress in generation of antibodies by ex vivo methods, systems for screening these, and the quest for higher affinity, more stable, optimally biodistributed antibody fragments, especially for solid tumors. The latest developments in engineering antibodies for removal or enhancement of effector functions (antibody-dependent cellular cytotoxicity (ADCC), phagosytosis, complement fixation (CDC) and halflife) through protein alteration or carbohydrate optimization may now enable generation of superior antibody therapeutics. Antibody conjugates, including immunotoxins and immunocytokines, as well as multivalent and multispecific antibodies confer expanded utility of therapeutic antibodies. Finally, research into the IgA / FcαRI system has now provided an additional route to therapeutic antibodies.
Keywords: antibodies, clinical trials, optimally biodistributed antibody, phagosytosis, carbohydrate optimization, therapeutic antibodies, anti-cancer mabs, fusion proteins
Current Pharmaceutical Biotechnology
Title: Engineering Antibodies for Therapy
Volume: 3 Issue: 3
Author(s): Leonard G. Presta
Affiliation:
Keywords: antibodies, clinical trials, optimally biodistributed antibody, phagosytosis, carbohydrate optimization, therapeutic antibodies, anti-cancer mabs, fusion proteins
Abstract: With eleven therapeutic antibodies approved worldwide and many more in clinical trials, research on antibody engineering has continued to escalate and expand. This review covers recent progress in generation of antibodies by ex vivo methods, systems for screening these, and the quest for higher affinity, more stable, optimally biodistributed antibody fragments, especially for solid tumors. The latest developments in engineering antibodies for removal or enhancement of effector functions (antibody-dependent cellular cytotoxicity (ADCC), phagosytosis, complement fixation (CDC) and halflife) through protein alteration or carbohydrate optimization may now enable generation of superior antibody therapeutics. Antibody conjugates, including immunotoxins and immunocytokines, as well as multivalent and multispecific antibodies confer expanded utility of therapeutic antibodies. Finally, research into the IgA / FcαRI system has now provided an additional route to therapeutic antibodies.
Export Options
About this article
Cite this article as:
Presta G. Leonard, Engineering Antibodies for Therapy, Current Pharmaceutical Biotechnology 2002; 3 (3) . https://dx.doi.org/10.2174/1389201023378256
DOI https://dx.doi.org/10.2174/1389201023378256 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Population Based Helicobacter pylori Screening and Eradication: Advances Versus Side Effects
Current Pharmaceutical Design Intracellular Fate of Peptide-Mediated Delivered Cargoes
Current Pharmaceutical Design Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Role of Antimicrobial Peptides Expressed by Host Cells Upon Infection by Helicobacter pylori
Protein & Peptide Letters “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery
Current Pharmaceutical Design SRC: Regulation, Role in Human Carcinogenesis and Pharmacological Inhibitors
Current Pharmaceutical Design The Role of Stem Cell Factor and Granulocyte-Colony Stimulating Factor in Treatment of Stroke
Recent Patents on CNS Drug Discovery (Discontinued) SiRNA Mediated Gene Silencing: Hurdles, Strategies and Applications
Pharmaceutical Nanotechnology Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Protective Effect of Heat Shock Proteins in the Nervous System
Current Neurovascular Research IL-6 Activated JAK/STAT3 Pathway and Sensitivity to Hsp90 Inhibitors in Multiple Myeloma
Current Medicinal Chemistry Recent Design and Structure-Activity Relationship Studies on the Modifications of DHFR Inhibitors as Anticancer Agents
Current Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Proteins of the Esterase Family: Patents for Some Proteins in Search of Metabolic Functions
Recent Patents on Biomarkers Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry Carbohydrate Microarray Technology for Functional Glycomics
Current Chemical Biology Sulfur-based Mechanistic Probes for Enzyme-catalyzed Reactions
Current Medicinal Chemistry Polycistronic Viral Vectors
Current Gene Therapy Fighting Fire with Fire: A Patent for the Combined Application of Oncolytic Herpes Viruses and Antiangiogenic Agents in the Battle Against Human Cancers
Recent Patents on Anti-Cancer Drug Discovery